Literature DB >> 9117408

Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum.

Z Pittel1, E Heldman, J Barg, R Haring, A Fisher.   

Abstract

It was previously shown by us and by others that activation of muscarinic acetylcholine receptors evoke amyloid precursor protein (APP) secretion in various cell lines. Here we examined if such muscarinic control of APP secretion occurs also in normal brain tissues. We found that the secretion of APP from rat cerebrocortical slices (rich in M1 receptors) was significantly increased by K+ depolarization, the non-selective agonist, carbachol (CCh), and the M1-selective agonist, AF102B. CCh also increased APP secretion from cerebellar slices (rich in M2 receptors) while AF102B had no significant effect in this brain region. Despite of its stimulatory effect on APP release in the cerebellum, CCh had no effect on phosphoinositide (PI) metabolism in this brain region. In the cerebral cortex PI metabolism was significantly increased by CCh but only partially increased by AF102B. These results suggest that APP secretion in the brain is mediated via muscarinic receptors. In the cerebral cortex APP secretion seems to be regulated via M1 receptors. Our results also suggest that PI metabolism is not a pronounced step in mediating APP processing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9117408     DOI: 10.1016/s0006-8993(96)01031-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 2.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 3.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

Review 4.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

5.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Authors:  Abraham Fisher; Rachel Brandeis; Rachel Haring Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Hagar Sonego; Itzhak Marcovitch; Zipora Pittel
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 6.  Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges.

Authors:  Marta Marquié; Mercè Boada; Amanda Cano; Patric Turowski; Miren Ettcheto; Jason Thomas Duskey; Giovanni Tosi; Elena Sánchez-López; Maria Luisa García; Antonio Camins; Eliana B Souto; Agustín Ruiz
Journal:  J Nanobiotechnology       Date:  2021-04-29       Impact factor: 10.435

Review 7.  M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Authors:  Abraham Fisher; Zipora Pittel; Rachel Haring; Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Inbal Egozi; Hagar Sonego; Itzhak Marcovitch; Rachel Brandeis
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.